Vaccine Makers Shed $28 Billion in Value After Moderna Miss
(Bloomberg) -- The leading Covid-19 vaccine developers are under pressure Thursday morning after an underwhelming earnings report from Moderna Inc. and lackluster expectations for sales of its Covid shot in the remainder of the year.
Early trading showed that biotechs including Moderna, Pfizer Inc., BioNTech SE and Novavax Inc. erased $28 billion in market value as jitters about the outlook for sales of the inoculations spread across Wall Street.
The disappointing results from Moderna contrast with strong sales for Pfizer and partner BioNTech's shot, which is projected to deliver $29 billion in revenue next year. Today's blow to the sector also comes a month after the group spiraled lower when a trial of Merck & Co.'s experimental pill showed it cut the risk of hospitalization and death in half.
Moderna shares tumble as much as 17% at the market open to send shares to the lowest level since mid-July while BioNTech and Novavax each drop more than 4%.
Investors are grappling with uncertainty over whether billions of dollars in sales will materialize as global economies reopen and other therapies are developed.Â
Wall Street analysts forecast Moderna's Covid vaccine will deliver nearly $20 billion in sales next year before tapering to $7.5 billion in 2024. However, the range of expectations is notable with a more than $20 billion spread between the highest and lowest estimates for 2022.
Investors will get another look at expectations for vaccine stocks when Novavax reports results after the bell Thursday. BioNTech's third-quarter earnings are expected before the stock market opens on Nov. 9.
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.